Interplay between Intrinsic and Innate Immunity during HIV Infection

Louis Bergantz, Frédéric Subra, Eric Deprez, Olivier Delelis, Clémence Richetta, Louis Bergantz, Frédéric Subra, Eric Deprez, Olivier Delelis, Clémence Richetta

Abstract

Restriction factors are antiviral components of intrinsic immunity which constitute a first line of defense by blocking different steps of the human immunodeficiency virus (HIV) replication cycle. In immune cells, HIV infection is also sensed by several pattern recognition receptors (PRRs), leading to type I interferon (IFN-I) and inflammatory cytokines production that upregulate antiviral interferon-stimulated genes (ISGs). Several studies suggest a link between these two types of immunity. Indeed, restriction factors, that are generally interferon-inducible, are able to modulate immune responses. This review highlights recent knowledge of the interplay between restriction factors and immunity inducing antiviral defenses. Counteraction of this intrinsic and innate immunity by HIV viral proteins will also be discussed.

Keywords: HIV-1; host restriction factors; immune responses; innate immune sensing; interferon; viral counteraction.

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
Simplified overview of several pattern recognition receptors (PRRs) signaling after pathogen-associated-molecular patterns (PAMPs) recognition. Signal transduction cascades leading to the production of type I interferon (IFN-I) and pro-inflammatory cytokines after Toll-like-receptors (TLRs) and retinoic acid-inducible gene I (RIG-I)-like receptors (RLRs) activation are described. See the text for more details. MyD88: myeloid differentiation factor 88, MAL: MyD88-adaptor-like, TRIF: TIR domain-containing adaptor-inducing IFN-β, TRAM: TRIF-related adaptor molecule, IRAK: interleukin-1 receptor-associated kinase, TRAF6: TNF receptor associated factor 6, TAK1: transforming growth factor beta-activated kinase 1, MAPK: mitogen-activated protein kinase, IKK: IκB kinase, NF-κB: nuclear factor-kappa B, IRF: IFN-regulatory factor, TBK1: tank-binding kinase 1, MAVS: mitochondrial antiviral-signaling, FADD: Fas-associated protein with death domain.
Figure 2
Figure 2
Schematic representation of HIV sensing by PRRs leading to the expression of antiviral restriction factors and shaping of immunity by restriction factors. Detection of HIV PAMPs by PRRs leads to activation of the transcription factors IRF and NF-κB driving the expression of IFN-I and inflammatory cytokines, respectively. IFN-I binds to IFNAR (IFN-α/β receptor chain) and activates transcription of interferon-stimulated genes (ISGs) including the restriction factors interferon-inducible transmembrane (IFITM) proteins, tripartite motif (TRIM)5α, apolipoprotein B mRNA-editing enzyme catalytic subunit-like 3G (APOBEC3G/A3G) and bone marrow stromal antigen 2 (BST-2). Antiviral functions of restriction factors are indicated by red arrows. Feedback of restriction factors on immunity are depicted by green arrows (induction: solid lines, inhibition: dotted lines). Counteractions by viral proteins are depicted in pink. Only restriction factors that are both induced by immunity and have an effect on immunity are illustrated. pDC: plasmacytoid dendritic cells, NK: natural killer cells, RT: reverse transcription, TLR: Toll-like receptors, RIG-I: retinoic acid-inducible gene I, cGAS: cyclic guanosine monophosphate (GMP)-adenosine monophosphate (AMP) synthase, cGAMP: cyclic GMP-AMP, STING: stimulator of interferon genes, IFI16: interferon gamma inducible protein 16, IRF: IFN-regulatory factor, ssRNA: single-stranded RNA, dsDNA: double-stranded DNA, TCR: T cell receptor, MHC-I pep: major histocompatibility complex I associated with a peptide.

References

    1. D’Urbano V., De Crignis E., Re M.C. Host restriction factors and human immunodeficiency virus (HIV-1): A dynamic interplay involving all phases of the viral life cycle. Curr. HIV Res. 2018;16:184–207. doi: 10.2174/1570162X16666180817115830.
    1. Zhang H., Yang B., Pomerantz R.J., Zhang C., Arunachalam S.C., Gao L. The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA. Nature. 2003;424:94–98. doi: 10.1038/nature01707.
    1. Mangeat B., Turelli P., Caron G., Friedli M., Perrin L., Trono D. Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts. Nature. 2003;424:99–103. doi: 10.1038/nature01709.
    1. Laguette N., Sobhian B., Casartelli N., Ringeard M., Chable-Bessia C., Ségéral E., Yatim A., Emiliani S., Schwartz O., Benkirane M. SAMHD1 is the dendritic- and myeloid-cell-specific HIV-1 restriction factor counteracted by Vpx. Nature. 2011;474:654–657. doi: 10.1038/nature10117.
    1. Hrecka K., Hao C., Gierszewska M., Swanson S.K., Kesik-Brodacka M., Srivastava S., Florens L., Washburn M.P., Skowronski J. Vpx relieves inhibition of HIV-1 infection of macrophages mediated by the SAMHD1 protein. Nature. 2011;474:658–661. doi: 10.1038/nature10195.
    1. Neil S.J.D., Zang T., Bieniasz P.D. Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu. Nature. 2008;451:425–430. doi: 10.1038/nature06553.
    1. Van Damme N., Goff D., Katsura C., Jorgenson R.L., Mitchell R., Johnson M.C., Stephens E.B., Guatelli J. The interferon-induced protein BST-2 restricts HIV-1 release and is downregulated from the cell surface by the viral Vpu protein. Cell Host Microbe. 2008;3:245–252. doi: 10.1016/j.chom.2008.03.001.
    1. Stremlau M., Owens C.M., Perron M.J., Kiessling M., Autissier P., Sodroski J. The cytoplasmic body component TRIM5alpha restricts HIV-1 infection in Old World monkeys. Nature. 2004;427:848–853. doi: 10.1038/nature02343.
    1. Lu J., Pan Q., Rong L., He W., Liu S.-L., Liang C. The IFITM proteins inhibit HIV-1 infection. J. Virol. 2011;85:2126–2137. doi: 10.1128/JVI.01531-10.
    1. Goujon C., Moncorgé O., Bauby H., Doyle T., Ward C.C., Schaller T., Hué S., Barclay W.S., Schulz R., Malim M.H. Human MX2 is an interferon-induced post-entry inhibitor of HIV-1 infection. Nature. 2013;502:559–562. doi: 10.1038/nature12542.
    1. Usami Y., Wu Y., Göttlinger H.G. SERINC3 and SERINC5 restrict HIV-1 infectivity and are counteracted by Nef. Nature. 2015;526:218–223. doi: 10.1038/nature15400.
    1. Li M., Kao E., Gao X., Sandig H., Limmer K., Pavon-Eternod M., Jones T.E., Landry S., Pan T., Weitzman M.D., et al. Codon-usage-based inhibition of HIV protein synthesis by human schlafen 11. Nature. 2012;491:125–128. doi: 10.1038/nature11433.
    1. Sadler A.J., Williams B.R.G. Interferon-inducible antiviral effectors. Nat. Rev. Immunol. 2008;8:559–568. doi: 10.1038/nri2314.
    1. Schoggins J.W., Rice C.M. Interferon-stimulated genes and their antiviral effector functions. Curr. Opin. Virol. 2011;1:519–525. doi: 10.1016/j.coviro.2011.10.008.
    1. van Montfoort N., Olagnier D., Hiscott J. Unmasking immune sensing of retroviruses: Interplay between innate sensors and host effectors. Cytokine Growth Factor Rev. 2014;25:657–668. doi: 10.1016/j.cytogfr.2014.08.006.
    1. Colomer-Lluch M., Ruiz A., Moris A., Prado J.G. Restriction Factors: From Intrinsic Viral Restriction to Shaping Cellular Immunity Against HIV-1. Front. Immunol. 2018;9:2876. doi: 10.3389/fimmu.2018.02876.
    1. O’Neill L.A.J., Bowie A.G. The family of five: TIR-domain-containing adaptors in Toll-like receptor signalling. Nat. Rev. Immunol. 2007;7:353–364. doi: 10.1038/nri2079.
    1. Medzhitov R., Janeway C. The Toll receptor family and microbial recognition. Trends Microbiol. 2000;8:452–456. doi: 10.1016/S0966-842X(00)01845-X.
    1. Thompson M.R., Kaminski J.J., Kurt-Jones E.A., Fitzgerald K.A. Pattern recognition receptors and the innate immune response to viral infection. Viruses. 2011;3:920–940. doi: 10.3390/v3060920.
    1. Chen K., Liu J., Cao X. Regulation of type I interferon signaling in immunity and inflammation: A comprehensive review. J. Autoimmun. 2017;83:1–11. doi: 10.1016/j.jaut.2017.03.008.
    1. Nazli A., Kafka J.K., Ferreira V.H., Anipindi V., Mueller K., Osborne B.J., Dizzell S., Chauvin S., Mian M.F., Ouellet M., et al. HIV-1 gp120 induces TLR2- and TLR4-mediated innate immune activation in human female genital epithelium. J. Immunol. 2013;191:4246–4258. doi: 10.4049/jimmunol.1301482.
    1. Heil F., Hemmi H., Hochrein H., Ampenberger F., Kirschning C., Akira S., Lipford G., Wagner H., Bauer S. Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8. Science. 2004;303:1526–1529. doi: 10.1126/science.1093620.
    1. Beignon A.-S., McKenna K., Skoberne M., Manches O., DaSilva I., Kavanagh D.G., Larsson M., Gorelick R.J., Lifson J.D., Bhardwaj N. Endocytosis of HIV-1 activates plasmacytoid dendritic cells via Toll-like receptor-viral RNA interactions. J. Clin. Invest. 2005;115:3265–3275. doi: 10.1172/JCI26032.
    1. Fonteneau J.-F., Larsson M., Beignon A.-S., McKenna K., Dasilva I., Amara A., Liu Y.-J., Lifson J.D., Littman D.R., Bhardwaj N. Human immunodeficiency virus type 1 activates plasmacytoid dendritic cells and concomitantly induces the bystander maturation of myeloid dendritic cells. J. Virol. 2004;78:5223–5232. doi: 10.1128/JVI.78.10.5223-5232.2004.
    1. Meier A., Alter G., Frahm N., Sidhu H., Li B., Bagchi A., Teigen N., Streeck H., Stellbrink H.-J., Hellman J., et al. MyD88-dependent immune activation mediated by human immunodeficiency virus type 1-encoded Toll-like receptor ligands. J. Virol. 2007;81:8180–8191. doi: 10.1128/JVI.00421-07.
    1. Chang J., Lindsay R.J., Kulkarni S., Lifson J.D., Carrington M., Altfeld M. Polymorphisms in interferon regulatory factor 7 reduce interferon-α responses of plasmacytoid dendritic cells to HIV-1. AIDS. 2011;25:715–717. doi: 10.1097/QAD.0b013e328343c186.
    1. Gringhuis S.I., van der Vlist M., van den Berg L.M., den Dunnen J., Litjens M., Geijtenbeek T.B.H. HIV-1 exploits innate signaling by TLR8 and DC-SIGN for productive infection of dendritic cells. Nat. Immunol. 2010;11:419–426. doi: 10.1038/ni.1858.
    1. Cingöz O., Goff S.P. HIV-1 is a poor inducer of innate immune responses. mBio. 2019;10 doi: 10.1128/mBio.02834-18.
    1. Martinson J.A., Roman-Gonzalez A., Tenorio A.R., Montoya C.J., Gichinga C.N., Rugeles M.T., Tomai M., Krieg A.M., Ghanekar S., Baum L.L., et al. Dendritic cells from HIV-1 infected individuals are less responsive to toll-like receptor (TLR) ligands. Cell. Immunol. 2007;250:75–84. doi: 10.1016/j.cellimm.2008.01.007.
    1. Blanchet F.P., Moris A., Nikolic D.S., Lehmann M., Cardinaud S., Stalder R., Garcia E., Dinkins C., Leuba F., Wu L., et al. Human immunodeficiency virus-1 inhibition of immunoamphisomes in dendritic cells impairs early innate and adaptive immune responses. Immunity. 2010;32:654–669. doi: 10.1016/j.immuni.2010.04.011.
    1. Henrick B.M., Yao X.-D., Zahoor M.A., Abimiku A., Osawe S., Rosenthal K.L. TLR10 senses HIV-1 proteins and significantly enhances HIV-1 infection. Front. Immunol. 2019;10:482. doi: 10.3389/fimmu.2019.00482.
    1. Berg R.K., Melchjorsen J., Rintahaka J., Diget E., Søby S., Horan K.A., Gorelick R.J., Matikainen S., Larsen C.S., Ostergaard L., et al. Genomic HIV RNA induces innate immune responses through RIG-I-dependent sensing of secondary-structured RNA. PLoS ONE. 2012;7:e29291. doi: 10.1371/journal.pone.0029291.
    1. Solis M., Nakhaei P., Jalalirad M., Lacoste J., Douville R., Arguello M., Zhao T., Laughrea M., Wainberg M.A., Hiscott J. RIG-I-mediated antiviral signaling is inhibited in HIV-1 infection by a protease-mediated sequestration of RIG-I. J. Virol. 2011;85:1224–1236. doi: 10.1128/JVI.01635-10.
    1. Nasr N., Alshehri A.A., Wright T.K., Shahid M., Heiner B.M., Harman A.N., Botting R.A., Helbig K.J., Beard M.R., Suzuki K., et al. Mechanism of interferon-stimulated gene induction in HIV-1-infected macrophages. J. Virol. 2017;91 doi: 10.1128/JVI.00744-17.
    1. Sun L., Wu J., Du F., Chen X., Chen Z.J. Cyclic GMP-AMP synthase is a cytosolic DNA sensor that activates the type I interferon pathway. Science. 2013;339:786–791. doi: 10.1126/science.1232458.
    1. Wu J., Sun L., Chen X., Du F., Shi H., Chen C., Chen Z.J. Cyclic GMP-AMP is an endogenous second messenger in innate immune signaling by cytosolic DNA. Science. 2013;339:826–830. doi: 10.1126/science.1229963.
    1. Zhang X., Shi H., Wu J., Zhang X., Sun L., Chen C., Chen Z.J. Cyclic GMP-AMP containing mixed phosphodiester linkages is an endogenous high-affinity ligand for STING. Mol. Cell. 2013;51:226–235. doi: 10.1016/j.molcel.2013.05.022.
    1. Ablasser A., Goldeck M., Cavlar T., Deimling T., Witte G., Röhl I., Hopfner K.-P., Ludwig J., Hornung V. cGAS produces a 2′-5′-linked cyclic dinucleotide second messenger that activates STING. Nature. 2013;498:380–384. doi: 10.1038/nature12306.
    1. Ablasser A., Schmid-Burgk J.L., Hemmerling I., Horvath G.L., Schmidt T., Latz E., Hornung V. Cell intrinsic immunity spreads to bystander cells via the intercellular transfer of cGAMP. Nature. 2013;503:530–534. doi: 10.1038/nature12640.
    1. Gao D., Wu J., Wu Y.-T., Du F., Aroh C., Yan N., Sun L., Chen Z.J. Cyclic GMP-AMP synthase is an innate immune sensor of HIV and other retroviruses. Science. 2013;341:903–906. doi: 10.1126/science.1240933.
    1. Manel N., Hogstad B., Wang Y., Levy D.E., Unutmaz D., Littman D.R. A cryptic sensor for HIV-1 activates antiviral innate immunity in dendritic cells. Nature. 2010;467:214–217. doi: 10.1038/nature09337.
    1. Peng K., Muranyi W., Glass B., Laketa V., Yant S.R., Tsai L., Cihlar T., Müller B., Kräusslich H.-G. Quantitative microscopy of functional HIV post-entry complexes reveals association of replication with the viral capsid. Elife. 2014;3:e04114. doi: 10.7554/eLife.04114.
    1. Chin C.R., Perreira J.M., Savidis G., Portmann J.M., Aker A.M., Feeley E.M., Smith M.C., Brass A.L. Direct visualization of HIV-1 replication intermediates shows that capsid and CPSF6 modulate HIV-1 intra-nuclear invasion and integration. Cell Rep. 2015;13:1717–1731. doi: 10.1016/j.celrep.2015.10.036.
    1. Lahaye X., Satoh T., Gentili M., Cerboni S., Conrad C., Hurbain I., El Marjou A., Lacabaratz C., Lelièvre J.-D., Manel N. The capsids of HIV-1 and HIV-2 determine immune detection of the viral cDNA by the innate sensor cGAS in dendritic cells. Immunity. 2013;39:1132–1142. doi: 10.1016/j.immuni.2013.11.002.
    1. Lahaye X., Gentili M., Silvin A., Conrad C., Picard L., Jouve M., Zueva E., Maurin M., Nadalin F., Knott G.J., et al. NONO detects the nuclear HIV capsid to promote cGAS-mediated innate immune activation. Cell. 2018;175:488–501.e22. doi: 10.1016/j.cell.2018.08.062.
    1. Jakobsen M.R., Bak R.O., Andersen A., Berg R.K., Jensen S.B., Tengchuan J., Jin T., Laustsen A., Hansen K., Ostergaard L., et al. IFI16 senses DNA forms of the lentiviral replication cycle and controls HIV-1 replication. Proc. Natl. Acad. Sci. USA. 2013;110:E4571–E4580. doi: 10.1073/pnas.1311669110.
    1. Guo H., Gao J., Taxman D.J., Ting J.P.Y., Su L. HIV-1 infection induces interleukin-1β production via TLR8 protein-dependent and NLRP3 inflammasome mechanisms in human monocytes. J. Biol. Chem. 2014;289:21716–21726. doi: 10.1074/jbc.M114.566620.
    1. Chattergoon M.A., Latanich R., Quinn J., Winter M.E., Buckheit R.W., Blankson J.N., Pardoll D., Cox A.L. HIV and HCV activate the inflammasome in monocytes and macrophages via endosomal Toll-like receptors without induction of type 1 interferon. PLoS Pathog. 2014;10:e1004082. doi: 10.1371/journal.ppat.1004082.
    1. Feria M.G., Taborda N.A., Hernandez J.C., Rugeles M.T. HIV replication is associated to inflammasomes activation, IL-1β, IL-18 and caspase-1 expression in GALT and peripheral blood. PLoS ONE. 2018;13 doi: 10.1371/journal.pone.0192845.
    1. Bailey C.C., Kondur H.R., Huang I.-C., Farzan M. Interferon-induced transmembrane protein 3 is a type II transmembrane protein. J. Biol. Chem. 2013;288:32184–32193. doi: 10.1074/jbc.M113.514356.
    1. Brass A.L., Huang I.-C., Benita Y., John S.P., Krishnan M.N., Feeley E.M., Ryan B.J., Weyer J.L., van der Weyden L., Fikrig E., et al. The IFITM proteins mediate cellular resistance to influenza A H1N1 virus, West Nile virus, and dengue virus. Cell. 2009;139:1243–1254. doi: 10.1016/j.cell.2009.12.017.
    1. Jiang D., Weidner J.M., Qing M., Pan X.-B., Guo H., Xu C., Zhang X., Birk A., Chang J., Shi P.-Y., et al. Identification of five interferon-induced cellular proteins that inhibit west nile virus and dengue virus infections. J. Virol. 2010;84:8332–8341. doi: 10.1128/JVI.02199-09.
    1. Savidis G., Perreira J.M., Portmann J.M., Meraner P., Guo Z., Green S., Brass A.L. The IFITMs inhibit zika virus replication. Cell Rep. 2016;15:2323–2330. doi: 10.1016/j.celrep.2016.05.074.
    1. Wilkins C., Woodward J., Lau D.T.-Y., Barnes A., Joyce M., McFarlane N., McKeating J.A., Tyrrell D.L., Gale M. IFITM1 is a tight junction protein that inhibits hepatitis C virus entry. Hepatology. 2013;57:461–469. doi: 10.1002/hep.26066.
    1. Huang I.-C., Bailey C.C., Weyer J.L., Radoshitzky S.R., Becker M.M., Chiang J.J., Brass A.L., Ahmed A.A., Chi X., Dong L., et al. Distinct patterns of IFITM-mediated restriction of filoviruses, SARS coronavirus, and influenza A virus. PLoS Pathog. 2011;7:e1001258. doi: 10.1371/journal.ppat.1001258.
    1. Wrensch F., Karsten C.B., Gnirß K., Hoffmann M., Lu K., Takada A., Winkler M., Simmons G., Pöhlmann S. Interferon-induced transmembrane protein-mediated inhibition of host cell entry of ebolaviruses. J. Infect. Dis. 2015;212:S210–S218. doi: 10.1093/infdis/jiv255.
    1. Mudhasani R., Tran J.P., Retterer C., Radoshitzky S.R., Kota K.P., Altamura L.A., Smith J.M., Packard B.Z., Kuhn J.H., Costantino J., et al. IFITM-2 and IFITM-3 but not IFITM-1 restrict Rift Valley fever virus. J. Virol. 2013;87:8451–8464. doi: 10.1128/JVI.03382-12.
    1. Zheng X.-Y., Bian P.-Y., Ye C.-T., Ye W., Ma H.-W., Tang K., Zhang C.-M., Lei Y.-F., Wei X., Wang P.-Z., et al. Interferon-induced transmembrane protein 3 inhibits hantaan virus infection, and its single nucleotide polymorphism rs12252 influences the severity of hemorrhagic fever with renal syndrome. Front. Immunol. 2016;7:535. doi: 10.3389/fimmu.2016.00535.
    1. Anafu A.A., Bowen C.H., Chin C.R., Brass A.L., Holm G.H. Interferon-inducible transmembrane protein 3 (IFITM3) restricts reovirus cell entry. J. Biol. Chem. 2013;288:17261–17271. doi: 10.1074/jbc.M112.438515.
    1. Li C., Du S., Tian M., Wang Y., Bai J., Tan P., Liu W., Yin R., Wang M., Jiang Y., et al. The host restriction factor interferon-inducible transmembrane protein 3 inhibits vaccinia virus infection. Front. Immunol. 2018;9:228. doi: 10.3389/fimmu.2018.00228.
    1. Smith S.E., Busse D.C., Binter S., Weston S., Diaz Soria C., Laksono B.M., Clare S., Van Nieuwkoop S., Van den Hoogen B.G., Clement M., et al. Interferon-induced transmembrane protein 1 restricts replication of viruses that enter cells via the plasma membrane. J. Virol. 2019;93 doi: 10.1128/JVI.02003-18.
    1. Li K., Jia R., Li M., Zheng Y.-M., Miao C., Yao Y., Ji H.-L., Geng Y., Qiao W., Albritton L.M., et al. A sorting signal suppresses IFITM1 restriction of viral entry. J. Biol. Chem. 2015;290:4248–4259. doi: 10.1074/jbc.M114.630780.
    1. Jia R., Xu F., Qian J., Yao Y., Miao C., Zheng Y.-M., Liu S.-L., Guo F., Geng Y., Qiao W., et al. Identification of an endocytic signal essential for the antiviral action of IFITM3. Cell. Microbiol. 2014;16:1080–1093. doi: 10.1111/cmi.12262.
    1. Li K., Markosyan R.M., Zheng Y.-M., Golfetto O., Bungart B., Li M., Ding S., He Y., Liang C., Lee J.C., et al. IFITM proteins restrict viral membrane hemifusion. PLoS Pathog. 2013;9:e1003124. doi: 10.1371/journal.ppat.1003124.
    1. Weidner J.M., Jiang D., Pan X.-B., Chang J., Block T.M., Guo J.-T. Interferon-induced cell membrane proteins, IFITM3 and tetherin, inhibit vesicular stomatitis virus infection via distinct mechanisms. J. Virol. 2010;84:12646–12657. doi: 10.1128/JVI.01328-10.
    1. Compton A.A., Bruel T., Porrot F., Mallet A., Sachse M., Euvrard M., Liang C., Casartelli N., Schwartz O. IFITM proteins incorporated into HIV-1 virions impair viral fusion and spread. Cell Host Microbe. 2014;16:736–747. doi: 10.1016/j.chom.2014.11.001.
    1. Desai T.M., Marin M., Chin C.R., Savidis G., Brass A.L., Melikyan G.B. IFITM3 restricts influenza A virus entry by blocking the formation of fusion pores following virus-endosome hemifusion. PLoS Pathog. 2014;10:e1004048. doi: 10.1371/journal.ppat.1004048.
    1. Spence J.S., He R., Hoffmann H.-H., Das T., Thinon E., Rice C.M., Peng T., Chandran K., Hang H.C. IFITM3 directly engages and shuttles incoming virus particles to lysosomes. Nat. Chem. Biol. 2019;15:259–268. doi: 10.1038/s41589-018-0213-2.
    1. Tartour K., Appourchaux R., Gaillard J., Nguyen X.-N., Durand S., Turpin J., Beaumont E., Roch E., Berger G., Mahieux R., et al. IFITM proteins are incorporated onto HIV-1 virion particles and negatively imprint their infectivity. Retrovirology. 2014;11:103. doi: 10.1186/s12977-014-0103-y.
    1. Yu J., Li M., Wilkins J., Ding S., Swartz T.H., Esposito A.M., Zheng Y.-M., Freed E.O., Liang C., Chen B.K., et al. IFITM proteins restrict HIV-1 infection by antagonizing the envelope glycoprotein. Cell Rep. 2015;13:145–156. doi: 10.1016/j.celrep.2015.08.055.
    1. Tartour K., Nguyen X.-N., Appourchaux R., Assil S., Barateau V., Bloyet L.-M., Burlaud Gaillard J., Confort M.-P., Escudero-Perez B., Gruffat H., et al. Interference with the production of infectious viral particles and bimodal inhibition of replication are broadly conserved antiviral properties of IFITMs. PLoS Pathog. 2017;13:e1006610. doi: 10.1371/journal.ppat.1006610.
    1. Appourchaux R., Delpeuch M., Zhong L., Burlaud-Gaillard J., Tartour K., Savidis G., Brass A., Etienne L., Roingeard P., Cimarelli A. Functional mapping of regions involved in the negative imprinting of virion particle infectivity and in target cell protection by interferon-induced transmembrane protein 3 against HIV-1. J. Virol. 2019;93 doi: 10.1128/JVI.01716-18.
    1. Jaffe E.A., Armellino D., Lam G., Cordon-Cardo C., Murray H.W., Evans R.L. IFN-gamma and IFN-alpha induce the expression and synthesis of Leu 13 antigen by cultured human endothelial cells. J. Immunol. 1989;143:3961–3966.
    1. Siegrist F., Ebeling M., Certa U. The small interferon-induced transmembrane genes and proteins. J. Interferon Cytokine Res. 2011;31:183–197. doi: 10.1089/jir.2010.0112.
    1. Allen E.K., Randolph A.G., Bhangale T., Dogra P., Ohlson M., Oshansky C.M., Zamora A.E., Shannon J.P., Finkelstein D., Dressen A., et al. SNP-mediated disruption of CTCF binding at the IFITM3 promoter is associated with risk of severe influenza in humans. Nat. Med. 2017;23:975–983. doi: 10.1038/nm.4370.
    1. Diamond M.S., Farzan M. The broad-spectrum antiviral functions of IFIT and IFITM proteins. Nat. Rev. Immunol. 2013;13:46–57. doi: 10.1038/nri3344.
    1. Zhao X., Li J., Winkler C.A., An P., Guo J.-T. IFITM genes, variants, and their roles in the control and pathogenesis of viral infections. Front. Microbiol. 2018;9:3228. doi: 10.3389/fmicb.2018.03228.
    1. Zhang Z., Liu J., Li M., Yang H., Zhang C. Evolutionary dynamics of the interferon-induced transmembrane gene family in vertebrates. PLoS ONE. 2012;7:e49265. doi: 10.1371/journal.pone.0049265.
    1. Ozato K., Shin D.-M., Chang T.-H., Morse H.C. TRIM family proteins and their emerging roles in innate immunity. Nat. Rev. Immunol. 2008;8:849–860. doi: 10.1038/nri2413.
    1. Hatakeyama S. TRIM family proteins: Roles in autophagy, immunity, and carcinogenesis. Trends Biochem. Sci. 2017;42:297–311. doi: 10.1016/j.tibs.2017.01.002.
    1. Rajsbaum R., García-Sastre A., Versteeg G.A. TRIMmunity: The roles of the TRIM E3-ubiquitin ligase family in innate antiviral immunity. J. Mol. Biol. 2014;426:1265–1284. doi: 10.1016/j.jmb.2013.12.005.
    1. Nisole S., Stoye J.P., Saïb A. TRIM family proteins: Retroviral restriction and antiviral defence. Nat. Rev. Microbiol. 2005;3:799–808. doi: 10.1038/nrmicro1248.
    1. Goff S.P. Retrovirus restriction factors. Mol. Cell. 2004;16:849–859. doi: 10.1016/j.molcel.2004.12.001.
    1. Hatziioannou T., Perez-Caballero D., Yang A., Cowan S., Bieniasz P.D. Retrovirus resistance factors Ref1 and Lv1 are species-specific variants of TRIM5alpha. Proc. Natl. Acad. Sci. USA. 2004;101:10774–10779. doi: 10.1073/pnas.0402361101.
    1. Keckesova Z., Ylinen L.M.J., Towers G.J. The human and African green monkey TRIM5alpha genes encode Ref1 and Lv1 retroviral restriction factor activities. Proc. Natl. Acad. Sci. USA. 2004;101:10780–10785. doi: 10.1073/pnas.0402474101.
    1. Perron M.J., Stremlau M., Song B., Ulm W., Mulligan R.C., Sodroski J. TRIM5alpha mediates the postentry block to N-tropic murine leukemia viruses in human cells. Proc. Natl. Acad. Sci. USA. 2004;101:11827–11832. doi: 10.1073/pnas.0403364101.
    1. Yap M.W., Nisole S., Lynch C., Stoye J.P. Trim5alpha protein restricts both HIV-1 and murine leukemia virus. Proc. Natl. Acad. Sci. USA. 2004;101:10786–10791. doi: 10.1073/pnas.0402876101.
    1. Grütter M.G., Luban J. TRIM5 structure, HIV-1 capsid recognition, and innate immune signaling. Curr. Opin. Virol. 2012;2:142–150. doi: 10.1016/j.coviro.2012.02.003.
    1. Pertel T., Hausmann S., Morger D., Züger S., Guerra J., Lascano J., Reinhard C., Santoni F.A., Uchil P.D., Chatel L., et al. TRIM5 is an innate immune sensor for the retrovirus capsid lattice. Nature. 2011;472:361–365. doi: 10.1038/nature09976.
    1. Nakayama E.E., Miyoshi H., Nagai Y., Shioda T. A specific region of 37 amino acid residues in the SPRY (B30.2) domain of African green monkey TRIM5alpha determines species-specific restriction of simian immunodeficiency virus SIVmac infection. J. Virol. 2005;79:8870–8877. doi: 10.1128/JVI.79.14.8870-8877.2005.
    1. Towers G., Bock M., Martin S., Takeuchi Y., Stoye J.P., Danos O. A conserved mechanism of retrovirus restriction in mammals. Proc. Natl. Acad. Sci. USA. 2000;97:12295–12299. doi: 10.1073/pnas.200286297.
    1. Ribeiro C.M.S., Sarrami-Forooshani R., Setiawan L.C., Zijlstra-Willems E.M., van Hamme J.L., Tigchelaar W., van der Wel N.N., Kootstra N.A., Gringhuis S.I., Geijtenbeek T.B.H. Receptor usage dictates HIV-1 restriction by human TRIM5α in dendritic cell subsets. Nature. 2016;540:448–452. doi: 10.1038/nature20567.
    1. Li Y.-L., Chandrasekaran V., Carter S.D., Woodward C.L., Christensen D.E., Dryden K.A., Pornillos O., Yeager M., Ganser-Pornillos B.K., Jensen G.J., et al. Primate TRIM5 proteins form hexagonal nets on HIV-1 capsids. Elife. 2016;5 doi: 10.7554/eLife.16269.
    1. Yang Y., Brandariz-Nuñez A., Fricke T., Ivanov D.N., Sarnak Z., Diaz-Griffero F. Binding of the rhesus TRIM5α PRYSPRY domain to capsid is necessary but not sufficient for HIV-1 restriction. Virology. 2014;448:217–228. doi: 10.1016/j.virol.2013.10.012.
    1. Ganser-Pornillos B.K., Chandrasekaran V., Pornillos O., Sodroski J.G., Sundquist W.I., Yeager M. Hexagonal assembly of a restricting TRIM5alpha protein. Proc. Natl. Acad. Sci. USA. 2011;108:534–539. doi: 10.1073/pnas.1013426108.
    1. Yap M.W., Nisole S., Stoye J.P. A single amino acid change in the SPRY domain of human Trim5alpha leads to HIV-1 restriction. Curr. Biol. 2005;15:73–78. doi: 10.1016/j.cub.2004.12.042.
    1. Li Y., Li X., Stremlau M., Lee M., Sodroski J. Removal of arginine 332 allows human TRIM5alpha to bind human immunodeficiency virus capsids and to restrict infection. J. Virol. 2006;80:6738–6744. doi: 10.1128/JVI.00270-06.
    1. Biris N., Tomashevski A., Bhattacharya A., Diaz-Griffero F., Ivanov D.N. Rhesus monkey TRIM5α SPRY domain recognizes multiple epitopes that span several capsid monomers on the surface of the HIV-1 mature viral core. J. Mol. Biol. 2013;425:5032–5044. doi: 10.1016/j.jmb.2013.07.025.
    1. Rahm N., Gfeller D., Snoeck J., Martinez R., McLaren P.J., Ortiz M., Ciuffi A., Telenti A. Susceptibility and adaptation to human TRIM5α alleles at positive selected sites in HIV-1 capsid. Virology. 2013;441:162–170. doi: 10.1016/j.virol.2013.03.021.
    1. Roa A., Hayashi F., Yang Y., Lienlaf M., Zhou J., Shi J., Watanabe S., Kigawa T., Yokoyama S., Aiken C., et al. RING domain mutations uncouple TRIM5α restriction of HIV-1 from inhibition of reverse transcription and acceleration of uncoating. J. Virol. 2012;86:1717–1727. doi: 10.1128/JVI.05811-11.
    1. Kutluay S.B., Perez-Caballero D., Bieniasz P.D. Fates of retroviral core components during unrestricted and TRIM5-restricted infection. PLoS Pathog. 2013;9:e1003214. doi: 10.1371/journal.ppat.1003214.
    1. Anderson J.L., Campbell E.M., Wu X., Vandegraaff N., Engelman A., Hope T.J. Proteasome inhibition reveals that a functional preintegration complex intermediate can be generated during restriction by diverse TRIM5 proteins. J. Virol. 2006;80:9754–9760. doi: 10.1128/JVI.01052-06.
    1. Wu X., Anderson J.L., Campbell E.M., Joseph A.M., Hope T.J. Proteasome inhibitors uncouple rhesus TRIM5alpha restriction of HIV-1 reverse transcription and infection. Proc. Natl. Acad. Sci. USA. 2006;103:7465–7470. doi: 10.1073/pnas.0510483103.
    1. Asaoka K., Ikeda K., Hishinuma T., Horie-Inoue K., Takeda S., Inoue S. A retrovirus restriction factor TRIM5alpha is transcriptionally regulated by interferons. Biochem. Biophys. Res. Commun. 2005;338:1950–1956. doi: 10.1016/j.bbrc.2005.10.173.
    1. Carthagena L., Parise M.C., Ringeard M., Chelbi-Alix M.K., Hazan U., Nisole S. Implication of TRIM alpha and TRIMCyp in interferon-induced anti-retroviral restriction activities. Retrovirology. 2008;5:59. doi: 10.1186/1742-4690-5-59.
    1. Sakuma R., Mael A.A., Ikeda Y. Alpha interferon enhances TRIM5alpha-mediated antiviral activities in human and rhesus monkey cells. J. Virol. 2007;81:10201–10206. doi: 10.1128/JVI.00419-07.
    1. Carthagena L., Bergamaschi A., Luna J.M., David A., Uchil P.D., Margottin-Goguet F., Mothes W., Hazan U., Transy C., Pancino G., et al. Human TRIM gene expression in response to interferons. PLoS ONE. 2009;4:e4894. doi: 10.1371/journal.pone.0004894.
    1. Rajsbaum R., Stoye J.P., O’Garra A. Type I interferon-dependent and -independent expression of tripartite motif proteins in immune cells. Eur. J. Immunol. 2008;38:619–630. doi: 10.1002/eji.200737916.
    1. Sheehy A.M., Gaddis N.C., Choi J.D., Malim M.H. Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature. 2002;418:646–650. doi: 10.1038/nature00939.
    1. Gabuzda D.H., Lawrence K., Langhoff E., Terwilliger E., Dorfman T., Haseltine W.A., Sodroski J. Role of vif in replication of human immunodeficiency virus type 1 in CD4+ T lymphocytes. J. Virol. 1992;66:6489–6495.
    1. Sheehy A.M., Gaddis N.C., Malim M.H. The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif. Nat. Med. 2003;9:1404–1407. doi: 10.1038/nm945.
    1. Zennou V., Perez-Caballero D., Göttlinger H., Bieniasz P.D. APOBEC3G incorporation into human immunodeficiency virus type 1 particles. J. Virol. 2004;78:12058–12061. doi: 10.1128/JVI.78.21.12058-12061.2004.
    1. Harris R.S., Bishop K.N., Sheehy A.M., Craig H.M., Petersen-Mahrt S.K., Watt I.N., Neuberger M.S., Malim M.H. DNA deamination mediates innate immunity to retroviral infection. Cell. 2003;113:803–809. doi: 10.1016/S0092-8674(03)00423-9.
    1. Lecossier D., Bouchonnet F., Clavel F., Hance A.J. Hypermutation of HIV-1 DNA in the Absence of the Vif Protein. Science. 2003;300:1112. doi: 10.1126/science.1083338.
    1. Suspène R., Sommer P., Henry M., Ferris S., Guétard D., Pochet S., Chester A., Navaratnam N., Wain-Hobson S., Vartanian J.-P. APOBEC3G is a single-stranded DNA cytidine deaminase and functions independently of HIV reverse transcriptase. Nucleic Acids Res. 2004;32:2421–2429. doi: 10.1093/nar/gkh554.
    1. Nowarski R., Prabhu P., Kenig E., Smith Y., Britan-Rosich E., Kotler M. APOBEC3G inhibits HIV-1 RNA elongation by inactivating the viral trans-activation response element. J. Mol. Biol. 2014;426:2840–2853. doi: 10.1016/j.jmb.2014.05.012.
    1. Langlois M.-A., Neuberger M.S. Human APOBEC3G can restrict retroviral infection in avian cells and acts independently of both UNG and SMUG1. J. Virol. 2008;82:4660–4664. doi: 10.1128/JVI.02469-07.
    1. Kaiser S.M., Emerman M. Uracil DNA glycosylase is dispensable for human immunodeficiency virus type 1 replication and does not contribute to the antiviral effects of the cytidine deaminase Apobec3G. J. Virol. 2006;80:875–882. doi: 10.1128/JVI.80.2.875-882.2006.
    1. Yang B., Chen K., Zhang C., Huang S., Zhang H. Virion-associated uracil DNA glycosylase-2 and apurinic/apyrimidinic endonuclease are involved in the degradation of APOBEC3G-edited nascent HIV-1 DNA. J. Biol. Chem. 2007;282:11667–11675. doi: 10.1074/jbc.M606864200.
    1. Pollpeter D., Parsons M., Sobala A.E., Coxhead S., Lang R.D., Bruns A.M., Papaioannou S., McDonnell J.M., Apolonia L., Chowdhury J.A., et al. Deep sequencing of HIV-1 reverse transcripts reveals the multifaceted antiviral functions of APOBEC3G. Nat. Microbiol. 2018;3:220–233. doi: 10.1038/s41564-017-0063-9.
    1. Guo F., Cen S., Niu M., Yang Y., Gorelick R.J., Kleiman L. The interaction of APOBEC3G with human immunodeficiency virus type 1 nucleocapsid inhibits tRNA3Lys annealing to viral RNA. J. Virol. 2007;81:11322–11331. doi: 10.1128/JVI.00162-07.
    1. Bishop K.N., Verma M., Kim E.-Y., Wolinsky S.M., Malim M.H. APOBEC3G inhibits elongation of HIV-1 reverse transcripts. PLoS Pathog. 2008;4:e1000231. doi: 10.1371/journal.ppat.1000231.
    1. Chaurasiya K.R., McCauley M.J., Wang W., Qualley D.F., Wu T., Kitamura S., Geertsema H., Chan D.S.B., Hertz A., Iwatani Y., et al. Oligomerization transforms human APOBEC3G from an efficient enzyme to a slowly dissociating nucleic acid-binding protein. Nat. Chem. 2014;6:28–33. doi: 10.1038/nchem.1795.
    1. Newman E.N.C., Holmes R.K., Craig H.M., Klein K.C., Lingappa J.R., Malim M.H., Sheehy A.M. Antiviral function of APOBEC3G can be dissociated from cytidine deaminase activity. Curr. Biol. 2005;15:166–170. doi: 10.1016/j.cub.2004.12.068.
    1. Gillick K., Pollpeter D., Phalora P., Kim E.-Y., Wolinsky S.M., Malim M.H. Suppression of HIV-1 infection by APOBEC3 proteins in primary human CD4(+) T cells is associated with inhibition of processive reverse transcription as well as excessive cytidine deamination. J. Virol. 2013;87:1508–1517. doi: 10.1128/JVI.02587-12.
    1. Suspène R., Guétard D., Henry M., Sommer P., Wain-Hobson S., Vartanian J.-P. Extensive editing of both hepatitis B virus DNA strands by APOBEC3 cytidine deaminases in vitro and in vivo. Proc. Natl. Acad. Sci. USA. 2005;102:8321–8326. doi: 10.1073/pnas.0408223102.
    1. Mahieux R., Suspène R., Delebecque F., Henry M., Schwartz O., Wain-Hobson S., Vartanian J.-P. Extensive editing of a small fraction of human T-cell leukemia virus type 1 genomes by four APOBEC3 cytidine deaminases. J. Gen. Virol. 2005;86:2489–2494. doi: 10.1099/vir.0.80973-0.
    1. Delebecque F., Suspène R., Calattini S., Casartelli N., Saïb A., Froment A., Wain-Hobson S., Gessain A., Vartanian J.-P., Schwartz O. Restriction of foamy viruses by APOBEC cytidine deaminases. J. Virol. 2006;80:605–614. doi: 10.1128/JVI.80.2.605-614.2006.
    1. Browne E.P., Littman D.R. Species-specific restriction of apobec3-mediated hypermutation. J. Virol. 2008;82:1305–1313. doi: 10.1128/JVI.01371-07.
    1. Okeoma C.M., Lovsin N., Peterlin B.M., Ross S.R. APOBEC3 inhibits mouse mammary tumour virus replication in vivo. Nature. 2007;445:927–930. doi: 10.1038/nature05540.
    1. Koning F.A., Newman E.N.C., Kim E.-Y., Kunstman K.J., Wolinsky S.M., Malim M.H. Defining APOBEC3 expression patterns in human tissues and hematopoietic cell subsets. J. Virol. 2009;83:9474–9485. doi: 10.1128/JVI.01089-09.
    1. Oliva H., Pacheco R., Martinez-Navio J.M., Rodríguez-García M., Naranjo-Gómez M., Climent N., Prado C., Gil C., Plana M., García F., et al. Increased expression with differential subcellular location of cytidine deaminase APOBEC3G in human CD4(+) T-cell activation and dendritic cell maturation. Immunol. Cell Biol. 2016;94:689–700. doi: 10.1038/icb.2016.28.
    1. Peng G., Lei K.J., Jin W., Greenwell-Wild T., Wahl S.M. Induction of APOBEC3 family proteins, a defensive maneuver underlying interferon-induced anti-HIV-1 activity. J. Exp. Med. 2006;203:41–46. doi: 10.1084/jem.20051512.
    1. Peng G., Greenwell-Wild T., Nares S., Jin W., Lei K.J., Rangel Z.G., Munson P.J., Wahl S.M. Myeloid differentiation and susceptibility to HIV-1 are linked to APOBEC3 expression. Blood. 2007;110:393–400. doi: 10.1182/blood-2006-10-051763.
    1. Sarkis P.T.N., Ying S., Xu R., Yu X.-F. STAT1-independent cell type-specific regulation of antiviral APOBEC3G by IFN-alpha. J. Immunol. 2006;177:4530–4540. doi: 10.4049/jimmunol.177.7.4530.
    1. Chen K., Huang J., Zhang C., Huang S., Nunnari G., Wang F., Tong X., Gao L., Nikisher K., Zhang H. Alpha interferon potently enhances the anti-human immunodeficiency virus type 1 activity of APOBEC3G in resting primary CD4 T cells. J. Virol. 2006;80:7645–7657. doi: 10.1128/JVI.00206-06.
    1. Pillai S.K., Abdel-Mohsen M., Guatelli J., Skasko M., Monto A., Fujimoto K., Yukl S., Greene W.C., Kovari H., Rauch A., et al. Role of retroviral restriction factors in the interferon-α-mediated suppression of HIV-1 in vivo. Proc. Natl. Acad. Sci. USA. 2012;109:3035–3040. doi: 10.1073/pnas.1111573109.
    1. Wang F.-X., Huang J., Zhang H., Ma X., Zhang H. APOBEC3G upregulation by alpha interferon restricts human immunodeficiency virus type 1 infection in human peripheral plasmacytoid dendritic cells. J. Gen. Virol. 2008;89:722–730. doi: 10.1099/vir.0.83530-0.
    1. Mohanram V., Sköld A.E., Bächle S.M., Pathak S.K., Spetz A.-L. IFN-α induces APOBEC3G, F, and A in immature dendritic cells and limits HIV-1 spread to CD4+ T cells. J. Immunol. 2013;190:3346–3353. doi: 10.4049/jimmunol.1201184.
    1. Argyris E.G., Acheampong E., Wang F., Huang J., Chen K., Mukhtar M., Zhang H. The interferon-induced expression of APOBEC3G in human blood-brain barrier exerts a potent intrinsic immunity to block HIV-1 entry to central nervous system. Virology. 2007;367:440–451. doi: 10.1016/j.virol.2007.06.010.
    1. Trapp S., Derby N.R., Singer R., Shaw A., Williams V.G., Turville S.G., Bess J.W., Lifson J.D., Robbiani M. Double-stranded RNA analog poly(I:C) inhibits human immunodeficiency virus amplification in dendritic cells via type I interferon-mediated activation of APOBEC3G. J. Virol. 2009;83:884–895. doi: 10.1128/JVI.00023-08.
    1. Zhou Y., Wang X., Liu M., Hu Q., Song L., Ye L., Zhou D., Ho W. A critical function of toll-like receptor-3 in the induction of anti-human immunodeficiency virus activities in macrophages. Immunology. 2010;131:40–49. doi: 10.1111/j.1365-2567.2010.03270.x.
    1. Chang M.O., Suzuki T., Yamamoto N., Watanabe M., Takaku H. HIV-1 Gag-virus-like particles inhibit HIV-1 replication in dendritic cells and T cells through IFN-α-dependent upregulation of APOBEC3G and 3F. J. Innate. Immun. 2012;4:579–590. doi: 10.1159/000339402.
    1. Stopak K.S., Chiu Y.-L., Kropp J., Grant R.M., Greene W.C. Distinct patterns of cytokine regulation of APOBEC3G expression and activity in primary lymphocytes, macrophages, and dendritic cells. J. Biol. Chem. 2007;282:3539–3546. doi: 10.1074/jbc.M610138200.
    1. Goldstone D.C., Ennis-Adeniran V., Hedden J.J., Groom H.C.T., Rice G.I., Christodoulou E., Walker P.A., Kelly G., Haire L.F., Yap M.W., et al. HIV-1 restriction factor SAMHD1 is a deoxynucleoside triphosphate triphosphohydrolase. Nature. 2011;480:379–382. doi: 10.1038/nature10623.
    1. Powell R.D., Holland P.J., Hollis T., Perrino F.W. Aicardi-Goutieres syndrome gene and HIV-1 restriction factor SAMHD1 is a dGTP-regulated deoxynucleotide triphosphohydrolase. J. Biol. Chem. 2011;286:43596–43600. doi: 10.1074/jbc.C111.317628.
    1. Lahouassa H., Daddacha W., Hofmann H., Ayinde D., Logue E.C., Dragin L., Bloch N., Maudet C., Bertrand M., Gramberg T., et al. SAMHD1 restricts the replication of human immunodeficiency virus type 1 by depleting the intracellular pool of deoxynucleoside triphosphates. Nat. Immunol. 2012;13:223–228. doi: 10.1038/ni.2236.
    1. Baldauf H.-M., Pan X., Erikson E., Schmidt S., Daddacha W., Burggraf M., Schenkova K., Ambiel I., Wabnitz G., Gramberg T., et al. SAMHD1 restricts HIV-1 infection in resting CD4(+) T cells. Nat. Med. 2012;18:1682–1687. doi: 10.1038/nm.2964.
    1. Descours B., Cribier A., Chable-Bessia C., Ayinde D., Rice G., Crow Y., Yatim A., Schwartz O., Laguette N., Benkirane M. SAMHD1 restricts HIV-1 reverse transcription in quiescent CD4(+) T-cells. Retrovirology. 2012;9:87. doi: 10.1186/1742-4690-9-87.
    1. Valle-Casuso J.C., Allouch A., David A., Lenzi G.M., Studdard L., Barré-Sinoussi F., Müller-Trutwin M., Kim B., Pancino G., Sáez-Cirión A. p21 restricts HIV-1 in monocyte-derived dendritic cells through the reduction of deoxynucleoside triphosphate biosynthesis and regulation of SAMHD1 antiviral activity. J. Virol. 2017;91 doi: 10.1128/JVI.01324-17.
    1. Jáuregui P., Landau N.R. DNA damage induces a SAMHD1-mediated block to the infection of macrophages by HIV-1. Sci. Rep. 2018;8:4153. doi: 10.1038/s41598-018-22432-4.
    1. Bonifati S., Daly M.B., St Gelais C., Kim S.H., Hollenbaugh J.A., Shepard C., Kennedy E.M., Kim D.-H., Schinazi R.F., Kim B., et al. SAMHD1 controls cell cycle status, apoptosis and HIV-1 infection in monocytic THP-1 cells. Virology. 2016;495:92–100. doi: 10.1016/j.virol.2016.05.002.
    1. Pauls E., Ruiz A., Badia R., Permanyer M., Gubern A., Riveira-Muñoz E., Torres-Torronteras J., Alvarez M., Mothe B., Brander C., et al. Cell cycle control and HIV-1 susceptibility are linked by CDK6-dependent CDK2 phosphorylation of SAMHD1 in myeloid and lymphoid cells. J. Immunol. 2014;193:1988–1997. doi: 10.4049/jimmunol.1400873.
    1. Yan J., Hao C., DeLucia M., Swanson S., Florens L., Washburn M.P., Ahn J., Skowronski J. CyclinA2-cyclin-dependent kinase regulates SAMHD1 protein phosphohydrolase domain. J. Biol. Chem. 2015;290:13279–13292. doi: 10.1074/jbc.M115.646588.
    1. Ruiz A., Pauls E., Badia R., Torres-Torronteras J., Riveira-Muñoz E., Clotet B., Martí R., Ballana E., Esté J.A. Cyclin D3-dependent control of the dNTP pool and HIV-1 replication in human macrophages. Cell Cycle. 2015;14:1657–1665. doi: 10.1080/15384101.2015.1030558.
    1. White T.E., Brandariz-Nuñez A., Valle-Casuso J.C., Amie S., Nguyen L.A., Kim B., Tuzova M., Diaz-Griffero F. The retroviral restriction ability of SAMHD1, but not its deoxynucleotide triphosphohydrolase activity, is regulated by phosphorylation. Cell Host Microbe. 2013;13:441–451. doi: 10.1016/j.chom.2013.03.005.
    1. Arnold L.H., Groom H.C.T., Kunzelmann S., Schwefel D., Caswell S.J., Ordonez P., Mann M.C., Rueschenbaum S., Goldstone D.C., Pennell S., et al. Phospho-dependent Regulation of SAMHD1 Oligomerisation Couples Catalysis and Restriction. PLoS Pathog. 2015;11:e1005194. doi: 10.1371/journal.ppat.1005194.
    1. Bhattacharya A., Wang Z., White T., Buffone C., Nguyen L.A., Shepard C.N., Kim B., Demeler B., Diaz-Griffero F., Ivanov D.N. Effects of T592 phosphomimetic mutations on tetramer stability and dNTPase activity of SAMHD1 can not explain the retroviral restriction defect. Sci. Rep. 2016;6:31353. doi: 10.1038/srep31353.
    1. Majer C., Schüssler J.M., König R. Intertwined: SAMHD1 cellular functions, restriction, and viral evasion strategies. Med. Microbiol. Immunol. 2019 doi: 10.1007/s00430-019-00593-x.
    1. Cribier A., Descours B., Valadão A.L.C., Laguette N., Benkirane M. Phosphorylation of SAMHD1 by cyclin A2/CDK1 regulates its restriction activity toward HIV-1. Cell Rep. 2013;3:1036–1043. doi: 10.1016/j.celrep.2013.03.017.
    1. Coiras M., Bermejo M., Descours B., Mateos E., García-Pérez J., López-Huertas M.-R., Lederman M.M., Benkirane M., Alcamí J. IL-7 induces SAMHD1 phosphorylation in CD4+ T lymphocytes, improving early steps of HIV-1 life cycle. Cell Rep. 2016;14:2100–2107. doi: 10.1016/j.celrep.2016.02.022.
    1. Beloglazova N., Flick R., Tchigvintsev A., Brown G., Popovic A., Nocek B., Yakunin A.F. Nuclease activity of the human SAMHD1 protein implicated in the Aicardi-Goutieres syndrome and HIV-1 restriction. J. Biol. Chem. 2013;288:8101–8110. doi: 10.1074/jbc.M112.431148.
    1. Seamon K.J., Sun Z., Shlyakhtenko L.S., Lyubchenko Y.L., Stivers J.T. SAMHD1 is a single-stranded nucleic acid binding protein with no active site-associated nuclease activity. Nucleic Acids Res. 2015;43:6486–6499. doi: 10.1093/nar/gkv633.
    1. Ryoo J., Choi J., Oh C., Kim S., Seo M., Kim S.-Y., Seo D., Kim J., White T.E., Brandariz-Nuñez A., et al. The ribonuclease activity of SAMHD1 is required for HIV-1 restriction. Nat. Med. 2014;20:936–941. doi: 10.1038/nm.3626.
    1. Choi J., Ryoo J., Oh C., Hwang S., Ahn K. SAMHD1 specifically restricts retroviruses through its RNase activity. Retrovirology. 2015;12:46. doi: 10.1186/s12977-015-0174-4.
    1. Antonucci J.M., St Gelais C., de Silva S., Yount J.S., Tang C., Ji X., Shepard C., Xiong Y., Kim B., Wu L. SAMHD1-mediated HIV-1 restriction in cells does not involve ribonuclease activity. Nat. Med. 2016;22:1072–1074. doi: 10.1038/nm.4163.
    1. White T.E., Brandariz-Nuñez A., Valle-Casuso J.C., Amie S., Nguyen L., Kim B., Brojatsch J., Diaz-Griffero F. Contribution of SAM and HD domains to retroviral restriction mediated by human SAMHD1. Virology. 2013;436:81–90. doi: 10.1016/j.virol.2012.10.029.
    1. Gramberg T., Kahle T., Bloch N., Wittmann S., Müllers E., Daddacha W., Hofmann H., Kim B., Lindemann D., Landau N.R. Restriction of diverse retroviruses by SAMHD1. Retrovirology. 2013;10:26. doi: 10.1186/1742-4690-10-26.
    1. Sze A., Belgnaoui S.M., Olagnier D., Lin R., Hiscott J., van Grevenynghe J. Host restriction factor SAMHD1 limits human T cell leukemia virus type 1 infection of monocytes via STING-mediated apoptosis. Cell Host Microbe. 2013;14:422–434. doi: 10.1016/j.chom.2013.09.009.
    1. Hollenbaugh J.A., Gee P., Baker J., Daly M.B., Amie S.M., Tate J., Kasai N., Kanemura Y., Kim D.-H., Ward B.M., et al. Host factor SAMHD1 restricts DNA viruses in non-dividing myeloid cells. PLoS Pathog. 2013;9:e1003481. doi: 10.1371/journal.ppat.1003481.
    1. St Gelais C., de Silva S., Amie S.M., Coleman C.M., Hoy H., Hollenbaugh J.A., Kim B., Wu L. SAMHD1 restricts HIV-1 infection in dendritic cells (DCs) by dNTP depletion, but its expression in DCs and primary CD4+ T-lymphocytes cannot be upregulated by interferons. Retrovirology. 2012;9:105. doi: 10.1186/1742-4690-9-105.
    1. Yang S., Zhan Y., Zhou Y., Jiang Y., Zheng X., Yu L., Tong W., Gao F., Li L., Huang Q., et al. Interferon regulatory factor 3 is a key regulation factor for inducing the expression of SAMHD1 in antiviral innate immunity. Sci. Rep. 2016;6:29665. doi: 10.1038/srep29665.
    1. Chen Z., Zhu M., Pan X., Zhu Y., Yan H., Jiang T., Shen Y., Dong X., Zheng N., Lu J., et al. Inhibition of Hepatitis B virus replication by SAMHD1. Biochem. Biophys. Res. Commun. 2014;450:1462–1468. doi: 10.1016/j.bbrc.2014.07.023.
    1. Zhu M., Lu J., Dong X., Zheng N., Li T., Chen Z., Pan X., Zhu Y., Yan H., Shen Y., et al. Interferon-stimulated gene factor 3 complex is required for the induction of sterile α motif and HD domain-containing protein 1 expression by interferon-α in SMMC-7721 cells. Mol. Med. Rep. 2015;12:7176–7180. doi: 10.3892/mmr.2015.4332.
    1. Pauls E., Jimenez E., Ruiz A., Permanyer M., Ballana E., Costa H., Nascimiento R., Parkhouse R.M., Peña R., Riveiro-Muñoz E., et al. Restriction of HIV-1 replication in primary macrophages by IL-12 and IL-18 through the upregulation of SAMHD1. J. Immunol. 2013;190:4736–4741. doi: 10.4049/jimmunol.1203226.
    1. Rennie M.L., McKelvie S.A., Bulloch E.M.M., Kingston R.L. Transient dimerization of human MxA promotes GTP hydrolysis, resulting in a mechanical power stroke. Structure. 2014;22:1433–1445. doi: 10.1016/j.str.2014.08.015.
    1. Aebi M., Fäh J., Hurt N., Samuel C.E., Thomis D., Bazzigher L., Pavlovic J., Haller O., Staeheli P. cDNA structures and regulation of two interferon-induced human Mx proteins. Mol. Cell. Biol. 1989;9:5062–5072. doi: 10.1128/MCB.9.11.5062.
    1. Horisberger M.A., McMaster G.K., Zeller H., Wathelet M.G., Dellis J., Content J. Cloning and sequence analyses of cDNAs for interferon- and virus-induced human Mx proteins reveal that they contain putative guanine nucleotide-binding sites: Functional study of the corresponding gene promoter. J. Virol. 1990;64:1171–1181.
    1. al-Masri A.N., Werfel T., Jakschies D., von Wussow P. Intracellular staining of Mx proteins in cells from peripheral blood, bone marrow and skin. MP Mol. Pathol. 1997;50:9–14. doi: 10.1136/mp.50.1.9.
    1. Sanda C., Weitzel P., Tsukahara T., Schaley J., Edenberg H.J., Stephens M.A., McClintick J.N., Blatt L.M., Li L., Brodsky L., et al. Differential gene induction by type I and type II interferons and their combination. J. Interferon Cytokine Res. 2006;26:462–472. doi: 10.1089/jir.2006.26.462.
    1. Wang X., Wang H., Liu M.-Q., Li J.-L., Zhou R.-H., Zhou Y., Wang Y.-Z., Zhou W., Ho W.-Z. IFN-λ inhibits drug-resistant HIV infection of macrophages. Front. Immunol. 2017;8:210. doi: 10.3389/fimmu.2017.00210.
    1. Kane M., Yadav S.S., Bitzegeio J., Kutluay S.B., Zang T., Wilson S.J., Schoggins J.W., Rice C.M., Yamashita M., Hatziioannou T., et al. MX2 is an interferon-induced inhibitor of HIV-1 infection. Nature. 2013;502:563–566. doi: 10.1038/nature12653.
    1. Matreyek K.A., Wang W., Serrao E., Singh P.K., Levin H.L., Engelman A. Host and viral determinants for MxB restriction of HIV-1 infection. Retrovirology. 2014;11:90. doi: 10.1186/s12977-014-0090-z.
    1. Fricke T., White T.E., Schulte B., de Souza Aranha Vieira D.A., Dharan A., Campbell E.M., Brandariz-Nuñez A., Diaz-Griffero F. MxB binds to the HIV-1 core and prevents the uncoating process of HIV-1. Retrovirology. 2014;11:68. doi: 10.1186/s12977-014-0068-x.
    1. Schulte B., Buffone C., Opp S., Di Nunzio F., De Souza Aranha Vieira D.A., Brandariz-Nuñez A., Diaz-Griffero F. Restriction of HIV-1 requires the N-terminal region of MxB as a capsid-binding motif but not as a nuclear localization signal. J. Virol. 2015;89:8599–8610. doi: 10.1128/JVI.00753-15.
    1. Liu Z., Pan Q., Ding S., Qian J., Xu F., Zhou J., Cen S., Guo F., Liang C. The interferon-inducible MxB protein inhibits HIV-1 infection. Cell Host Microbe. 2013;14:398–410. doi: 10.1016/j.chom.2013.08.015.
    1. Dicks M.D.J., Goujon C., Pollpeter D., Betancor G., Apolonia L., Bergeron J.R.C., Malim M.H. Oligomerization requirements for MX2-mediated suppression of HIV-1 infection. J. Virol. 2016;90:22–32. doi: 10.1128/JVI.02247-15.
    1. Buffone C., Schulte B., Opp S., Diaz-Griffero F. Contribution of MxB oligomerization to HIV-1 capsid binding and restriction. J. Virol. 2015;89:3285–3294. doi: 10.1128/JVI.03730-14.
    1. Alvarez F.J.D., He S., Perilla J.R., Jang S., Schulten K., Engelman A.N., Scheres S.H.W., Zhang P. CryoEM structure of MxB reveals a novel oligomerization interface critical for HIV restriction. Sci. Adv. 2017;3:e1701264. doi: 10.1126/sciadv.1701264.
    1. Buffone C., Kutzner J., Opp S., Martinez-Lopez A., Selyutina A., Coggings S.A., Studdard L.R., Ding L., Kim B., Spearman P., et al. The ability of SAMHD1 to block HIV-1 but not SIV requires expression of MxB. Virology. 2019;531:260–268. doi: 10.1016/j.virol.2019.03.018.
    1. Sironi M., Biasin M., Cagliani R., Gnudi F., Saulle I., Ibba S., Filippi G., Yahyaei S., Tresoldi C., Riva S., et al. Evolutionary analysis identifies an MX2 haplotype associated with natural resistance to HIV-1 infection. Mol. Biol. Evol. 2014;31:2402–2414. doi: 10.1093/molbev/msu193.
    1. Crameri M., Bauer M., Caduff N., Walker R., Steiner F., Franzoso F.D., Gujer C., Boucke K., Kucera T., Zbinden A., et al. MxB is an interferon-induced restriction factor of human herpesviruses. Nat. Commun. 2018;9:1980. doi: 10.1038/s41467-018-04379-2.
    1. Li N., Luo F., Chen Q., Zhu N., Wang H., Xie L., Xiong H., Yue M., Zhang Y., Feng Y., et al. IFN-λs inhibit Hantaan virus infection through the JAK-STAT pathway and expression of Mx2 protein. Genes Immun. 2019;20:234–244. doi: 10.1038/s41435-018-0028-x.
    1. Kupzig S., Korolchuk V., Rollason R., Sugden A., Wilde A., Banting G. Bst-2/HM1.24 is a raft-associated apical membrane protein with an unusual topology. Traffic. 2003;4:694–709. doi: 10.1034/j.1600-0854.2003.00129.x.
    1. Perez-Caballero D., Zang T., Ebrahimi A., McNatt M.W., Gregory D.A., Johnson M.C., Bieniasz P.D. Tetherin inhibits HIV-1 release by directly tethering virions to cells. Cell. 2009;139:499–511. doi: 10.1016/j.cell.2009.08.039.
    1. Fitzpatrick K., Skasko M., Deerinck T.J., Crum J., Ellisman M.H., Guatelli J. Direct restriction of virus release and incorporation of the interferon-induced protein BST-2 into HIV-1 particles. PLoS Pathog. 2010;6:e1000701. doi: 10.1371/journal.ppat.1000701.
    1. Hammonds J., Wang J.-J., Yi H., Spearman P. Immunoelectron microscopic evidence for Tetherin/BST2 as the physical bridge between HIV-1 virions and the plasma membrane. PLoS Pathog. 2010;6:e1000749. doi: 10.1371/journal.ppat.1000749.
    1. Venkatesh S., Bieniasz P.D. Mechanism of HIV-1 virion entrapment by tetherin. PLoS Pathog. 2013;9:e1003483. doi: 10.1371/journal.ppat.1003483.
    1. Miyakawa K., Ryo A., Murakami T., Ohba K., Yamaoka S., Fukuda M., Guatelli J., Yamamoto N. BCA2/Rabring7 promotes tetherin-dependent HIV-1 restriction. PLoS Pathog. 2009;5:e1000700. doi: 10.1371/journal.ppat.1000700.
    1. Cocka L.J., Bates P. Identification of alternatively translated Tetherin isoforms with differing antiviral and signaling activities. PLoS Pathog. 2012;8:e1002931. doi: 10.1371/journal.ppat.1002931.
    1. Erikson E., Adam T., Schmidt S., Lehmann-Koch J., Over B., Goffinet C., Harter C., Bekeredjian-Ding I., Sertel S., Lasitschka F., et al. In vivo expression profile of the antiviral restriction factor and tumor-targeting antigen CD317/BST-2/HM1.24/tetherin in humans. Proc. Natl. Acad. Sci. USA. 2011;108:13688–13693. doi: 10.1073/pnas.1101684108.
    1. Ohtomo T., Sugamata Y., Ozaki Y., Ono K., Yoshimura Y., Kawai S., Koishihara Y., Ozaki S., Kosaka M., Hirano T., et al. Molecular cloning and characterization of a surface antigen preferentially overexpressed on multiple myeloma cells. Biochem. Biophys. Res. Commun. 1999;258:583–591. doi: 10.1006/bbrc.1999.0683.
    1. Yoo H., Park S.-H., Ye S.-K., Kim M. IFN-γ-induced BST2 mediates monocyte adhesion to human endothelial cells. Cell. Immunol. 2011;267:23–29. doi: 10.1016/j.cellimm.2010.10.011.
    1. Amet T., Byrd D., Hu N., Sun Q., Li F., Zhao Y., Hu S., Grantham A., Yu Q. BST-2 expression in human hepatocytes is inducible by all three types of interferons and restricts production of hepatitis C virus. Curr. Mol. Med. 2014;14:349–360. doi: 10.2174/1566524013666131118111719.
    1. Holmgren A.M., Miller K.D., Cavanaugh S.E., Rall G.F. Bst2/Tetherin is induced in neurons by type I interferon and viral infection but is dispensable for protection against neurotropic viral challenge. J. Virol. 2015;89:11011–11018. doi: 10.1128/JVI.01745-15.
    1. Blanchet F.P., Stalder R., Czubala M., Lehmann M., Rio L., Mangeat B., Piguet V. TLR-4 engagement of dendritic cells confers a BST-2/tetherin-mediated restriction of HIV-1 infection to CD4+ T cells across the virological synapse. Retrovirology. 2013;10:6. doi: 10.1186/1742-4690-10-6.
    1. Homann S., Smith D., Little S., Richman D., Guatelli J. Upregulation of BST-2/Tetherin by HIV infection in vivo. J. Virol. 2011;85:10659–10668. doi: 10.1128/JVI.05524-11.
    1. Guzzo C., Jung M., Graveline A., Banfield B.W., Gee K. IL-27 increases BST-2 expression in human monocytes and T cells independently of type I IFN. Sci. Rep. 2012;2:974. doi: 10.1038/srep00974.
    1. Bego M.G., Mercier J., Cohen E.A. Virus-activated interferon regulatory factor 7 upregulates expression of the interferon-regulated BST2 gene independently of interferon signaling. J. Virol. 2012;86:3513–3527. doi: 10.1128/JVI.06971-11.
    1. Bauman D.R., Bitmansour A.D., McDonald J.G., Thompson B.M., Liang G., Russell D.W. 25-Hydroxycholesterol secreted by macrophages in response to Toll-like receptor activation suppresses immunoglobulin A production. Proc. Natl. Acad. Sci. USA. 2009;106:16764–16769. doi: 10.1073/pnas.0909142106.
    1. Park K., Scott A.L. Cholesterol 25-hydroxylase production by dendritic cells and macrophages is regulated by type I interferons. J. Leukoc. Biol. 2010;88:1081–1087. doi: 10.1189/jlb.0610318.
    1. Liu S.-Y., Aliyari R., Chikere K., Li G., Marsden M.D., Smith J.K., Pernet O., Guo H., Nusbaum R., Zack J.A., et al. Interferon-inducible cholesterol-25-hydroxylase broadly inhibits viral entry by production of 25-hydroxycholesterol. Immunity. 2013;38:92–105. doi: 10.1016/j.immuni.2012.11.005.
    1. Chen Y., Wang S., Yi Z., Tian H., Aliyari R., Li Y., Chen G., Liu P., Zhong J., Chen X., et al. Interferon-inducible cholesterol-25-hydroxylase inhibits hepatitis C virus replication via distinct mechanisms. Sci. Rep. 2014;4:7242. doi: 10.1038/srep07242.
    1. Li C., Deng Y.-Q., Wang S., Ma F., Aliyari R., Huang X.-Y., Zhang N.-N., Watanabe M., Dong H.-L., Liu P., et al. 25-Hydroxycholesterol protects host against zika virus infection and its associated microcephaly in a mouse model. Immunity. 2017;46:446–456. doi: 10.1016/j.immuni.2017.02.012.
    1. Gomes B., Gonçalves S., Disalvo A., Hollmann A., Santos N.C. Effect of 25-hydroxycholesterol in viral membrane fusion: Insights on HIV inhibition. Biochim. Biophys. Acta Biomembr. 2018;1860:1171–1178. doi: 10.1016/j.bbamem.2018.02.001.
    1. Gao G., Guo X., Goff S.P. Inhibition of retroviral RNA production by ZAP, a CCCH-type zinc finger protein. Science. 2002;297:1703–1706. doi: 10.1126/science.1074276.
    1. Bick M.J., Carroll J.-W.N., Gao G., Goff S.P., Rice C.M., MacDonald M.R. Expression of the zinc-finger antiviral protein inhibits alphavirus replication. J. Virol. 2003;77:11555–11562. doi: 10.1128/JVI.77.21.11555-11562.2003.
    1. Müller S., Möller P., Bick M.J., Wurr S., Becker S., Günther S., Kümmerer B.M. Inhibition of filovirus replication by the zinc finger antiviral protein. J. Virol. 2007;81:2391–2400. doi: 10.1128/JVI.01601-06.
    1. Mao R., Nie H., Cai D., Zhang J., Liu H., Yan R., Cuconati A., Block T.M., Guo J.-T., Guo H. Inhibition of hepatitis B virus replication by the host zinc finger antiviral protein. PLoS Pathog. 2013;9:e1003494. doi: 10.1371/journal.ppat.1003494.
    1. Li M., Yan K., Wei L., Yang J., Lu C., Xiong F., Zheng C., Xu W. Zinc finger antiviral protein inhibits coxsackievirus B3 virus replication and protects against viral myocarditis. Antiviral Res. 2015;123:50–61. doi: 10.1016/j.antiviral.2015.09.001.
    1. Chiu H.-P., Chiu H., Yang C.-F., Lee Y.-L., Chiu F.-L., Kuo H.-C., Lin R.-J., Lin Y.-L. Inhibition of Japanese encephalitis virus infection by the host zinc-finger antiviral protein. PLoS Pathog. 2018;14:e1007166. doi: 10.1371/journal.ppat.1007166.
    1. Guo X., Carroll J.-W.N., Macdonald M.R., Goff S.P., Gao G. The zinc finger antiviral protein directly binds to specific viral mRNAs through the CCCH zinc finger motifs. J. Virol. 2004;78:12781–12787. doi: 10.1128/JVI.78.23.12781-12787.2004.
    1. Guo X., Ma J., Sun J., Gao G. The zinc-finger antiviral protein recruits the RNA processing exosome to degrade the target mRNA. Proc. Natl. Acad. Sci. USA. 2007;104:151–156. doi: 10.1073/pnas.0607063104.
    1. Chen G., Guo X., Lv F., Xu Y., Gao G. p72 DEAD box RNA helicase is required for optimal function of the zinc-finger antiviral protein. Proc. Natl. Acad. Sci. USA. 2008;105:4352–4357. doi: 10.1073/pnas.0712276105.
    1. Zhu Y., Chen G., Lv F., Wang X., Ji X., Xu Y., Sun J., Wu L., Zheng Y.-T., Gao G. Zinc-finger antiviral protein inhibits HIV-1 infection by selectively targeting multiply spliced viral mRNAs for degradation. Proc. Natl. Acad. Sci. USA. 2011;108:15834–15839. doi: 10.1073/pnas.1101676108.
    1. Zhu Y., Wang X., Goff S.P., Gao G. Translational repression precedes and is required for ZAP-mediated mRNA decay. EMBO J. 2012;31:4236–4246. doi: 10.1038/emboj.2012.271.
    1. Zheng X., Wang X., Tu F., Wang Q., Fan Z., Gao G. TRIM25 is required for the antiviral activity of zinc finger antiviral protein. J. Virol. 2017;91 doi: 10.1128/JVI.00088-17.
    1. Li M.M.H., Lau Z., Cheung P., Aguilar E.G., Schneider W.M., Bozzacco L., Molina H., Buehler E., Takaoka A., Rice C.M., et al. TRIM25 enhances the antiviral action of zinc-finger antiviral protein (ZAP) PLoS Pathog. 2017;13:e1006145. doi: 10.1371/journal.ppat.1006145.
    1. Kerns J.A., Emerman M., Malik H.S. Positive selection and increased antiviral activity associated with the PARP-containing isoform of human zinc-finger antiviral protein. PLoS Genet. 2008;4:e21. doi: 10.1371/journal.pgen.0040021.
    1. Hayakawa S., Shiratori S., Yamato H., Kameyama T., Kitatsuji C., Kashigi F., Goto S., Kameoka S., Fujikura D., Yamada T., et al. ZAPS is a potent stimulator of signaling mediated by the RNA helicase RIG-I during antiviral responses. Nat. Immunol. 2011;12:37–44. doi: 10.1038/ni.1963.
    1. Li M.M.H., Aguilar E.G., Michailidis E., Pabon J., Park P., Wu X., de Jong Y.P., Schneider W.M., Molina H., Rice C.M., et al. Characterization of novel splice variants of zinc finger antiviral protein (ZAP) J. Virol. 2019 doi: 10.1128/JVI.00715-19.
    1. Erazo A., Goff S.P. Nuclear matrix protein Matrin 3 is a regulator of ZAP-mediated retroviral restriction. Retrovirology. 2015;12:57. doi: 10.1186/s12977-015-0182-4.
    1. Yedavalli V.S.R.K., Jeang K.-T. Matrin 3 is a co-factor for HIV-1 Rev in regulating post-transcriptional viral gene expression. Retrovirology. 2011;8:61. doi: 10.1186/1742-4690-8-61.
    1. van Weringh A., Ragonnet-Cronin M., Pranckeviciene E., Pavon-Eternod M., Kleiman L., Xia X. HIV-1 modulates the tRNA pool to improve translation efficiency. Mol. Biol. Evol. 2011;28:1827–1834. doi: 10.1093/molbev/msr005.
    1. Lin Y.-Z., Sun L.-K., Zhu D.-T., Hu Z., Wang X.-F., Du C., Wang Y.-H., Wang X.-J., Zhou J.-H. Equine schlafen 11 restricts the production of equine infectious anemia virus via a codon usage-dependent mechanism. Virology. 2016;495:112–121. doi: 10.1016/j.virol.2016.04.024.
    1. Stabell A.C., Hawkins J., Li M., Gao X., David M., Press W.H., Sawyer S.L. Non-human primate Schlafen11 inhibits production of both host and viral proteins. PLoS Pathog. 2016;12:e1006066. doi: 10.1371/journal.ppat.1006066.
    1. Li J., Peet G.W., Balzarano D., Li X., Massa P., Barton R.W., Marcu K.B. Novel NEMO/IκB kinase and NF-κB target genes at the Pre-B to immature B cell transition. J. Biol. Chem. 2001;276:18579–18590. doi: 10.1074/jbc.M100846200.
    1. Sen G.C., Sarkar S.N. The interferon-stimulated genes: Targets of direct signaling by interferons, double-stranded RNA, and viruses. In: Pitha P.M., editor. Interferon: The 50th Anniversary. Springer; Berlin/Heidelberg, Germany: 2007. pp. 233–250. Current Topics in Microbiology and Immunology.
    1. Villarroya-Beltri C., Guerra S., Sánchez-Madrid F. ISGylation—A key to lock the cell gates for preventing the spread of threats. J. Cell. Sci. 2017;130:2961–2969. doi: 10.1242/jcs.205468.
    1. Okumura A., Lu G., Pitha-Rowe I., Pitha P.M. Innate antiviral response targets HIV-1 release by the induction of ubiquitin-like protein ISG15. Proc. Natl. Acad. Sci. USA. 2006;103:1440–1445. doi: 10.1073/pnas.0510518103.
    1. Malakhova O.A., Zhang D.-E. ISG15 inhibits Nedd4 ubiquitin E3 activity and enhances the innate antiviral response. J. Biol. Chem. 2008;283:8783–8787. doi: 10.1074/jbc.C800030200.
    1. Wong J.J.Y., Pung Y.F., Sze N.S.-K., Chin K.-C. HERC5 is an IFN-induced HECT-type E3 protein ligase that mediates type I IFN-induced ISGylation of protein targets. Proc. Natl. Acad. Sci. USA. 2006;103:10735–10740. doi: 10.1073/pnas.0600397103.
    1. Woods M.W., Kelly J.N., Hattlmann C.J., Tong J.G.K., Xu L.S., Coleman M.D., Quest G.R., Smiley J.R., Barr S.D. Human HERC5 restricts an early stage of HIV-1 assembly by a mechanism correlating with the ISGylation of Gag. Retrovirology. 2011;8:95. doi: 10.1186/1742-4690-8-95.
    1. Pincetic A., Kuang Z., Seo E.J., Leis J. The interferon-induced gene ISG15 blocks retrovirus release from cells late in the budding process. J. Virol. 2010;84:4725–4736. doi: 10.1128/JVI.02478-09.
    1. Scagnolari C., Monteleone K., Selvaggi C., Pierangeli A., D’Ettorre G., Mezzaroma I., Turriziani O., Gentile M., Vullo V., Antonelli G. ISG15 expression correlates with HIV-1 viral load and with factors regulating T cell response. Immunobiology. 2016;221:282–290. doi: 10.1016/j.imbio.2015.10.007.
    1. Gargan S., Ahmed S., Mahony R., Bannan C., Napoletano S., O’Farrelly C., Borrow P., Bergin C., Stevenson N.J. HIV-1 promotes the degradation of components of the type 1 IFN JAK/STAT pathway and blocks anti-viral ISG induction. EBioMedicine. 2018;30:203–216. doi: 10.1016/j.ebiom.2018.03.006.
    1. Vestal D.J., Jeyaratnam J.A. The guanylate-binding proteins: Emerging insights into the biochemical properties and functions of this family of large interferon-induced guanosine triphosphatase. J. Interferon Cytokine Res. 2011;31:89–97. doi: 10.1089/jir.2010.0102.
    1. McLaren P.J., Gawanbacht A., Pyndiah N., Krapp C., Hotter D., Kluge S.F., Götz N., Heilmann J., Mack K., Sauter D., et al. Identification of potential HIV restriction factors by combining evolutionary genomic signatures with functional analyses. Retrovirology. 2015;12:41. doi: 10.1186/s12977-015-0165-5.
    1. Krapp C., Hotter D., Gawanbacht A., McLaren P.J., Kluge S.F., Stürzel C.M., Mack K., Reith E., Engelhart S., Ciuffi A., et al. Guanylate binding protein (GBP) 5 is an interferon-inducible inhibitor of HIV-1 infectivity. Cell Host Microbe. 2016;19:504–514. doi: 10.1016/j.chom.2016.02.019.
    1. Hotter D., Sauter D., Kirchhoff F. Guanylate binding protein 5: Impairing virion infectivity by targeting retroviral envelope glycoproteins. Small GTPases. 2017;8:31–37. doi: 10.1080/21541248.2016.1189990.
    1. Fujiwara Y., Hizukuri Y., Yamashiro K., Makita N., Ohnishi K., Takeya M., Komohara Y., Hayashi Y. Guanylate-binding protein 5 is a marker of interferon-γ-induced classically activated macrophages. Clin. Transl. Immunol. 2016;5:e111. doi: 10.1038/cti.2016.59.
    1. Richards K.H., Clapham P.R. Effects of vpu start-codon mutations on human immunodeficiency virus type 1 replication in macrophages. J. Gen. Virol. 2007;88:2780–2792. doi: 10.1099/vir.0.83120-0.
    1. Alteber Z., Sharbi-Yunger A., Pevsner-Fischer M., Blat D., Roitman L., Tzehoval E., Elinav E., Eisenbach L. The anti-inflammatory IFITM genes ameliorate colitis and partially protect from tumorigenesis by changing immunity and microbiota. Immunol. Cell Biol. 2018;96:284–297. doi: 10.1111/imcb.12000.
    1. Yánez D.C., Sahni H., Ross S., Solanki A., Lau C.-I., Papaioannou E., Barbarulo A., Powell R., Lange U.C., Adams D.J., et al. IFITM proteins drive type 2 T helper cell differentiation and exacerbate allergic airway inflammation. Eur. J. Immunol. 2019;49:66–78. doi: 10.1002/eji.201847692.
    1. Tareen S.U., Emerman M. Human Trim5α has additional activities that are uncoupled from retroviral capsid recognition. Virology. 2011;409:113–120. doi: 10.1016/j.virol.2010.09.018.
    1. Yudina Z., Roa A., Johnson R., Biris N., de Souza Aranha Vieira D.A., Tsiperson V., Reszka N., Taylor A.B., Hart P.J., Demeler B., et al. RING dimerization links higher-order assembly of TRIM5α to synthesis of K63-linked polyubiquitin. Cell Rep. 2015;12:788–797. doi: 10.1016/j.celrep.2015.06.072.
    1. Nepveu-Traversy M.-É., Berthoux L. The conserved sumoylation consensus site in TRIM5α modulates its immune activation functions. Virus Res. 2014;184:30–38. doi: 10.1016/j.virusres.2014.02.013.
    1. Dutrieux J., Portilho D.M., Arhel N.J., Hazan U., Nisole S. TRIM5α is a SUMO substrate. Retrovirology. 2015;12:28. doi: 10.1186/s12977-015-0155-7.
    1. Versteeg G.A., Rajsbaum R., Sánchez-Aparicio M.T., Maestre A.M., Valdiviezo J., Shi M., Inn K.-S., Fernandez-Sesma A., Jung J., García-Sastre A. The E3-ligase TRIM family of proteins regulates signaling pathways triggered by innate immune pattern-recognition receptors. Immunity. 2013;38:384–398. doi: 10.1016/j.immuni.2012.11.013.
    1. Uchil P.D., Hinz A., Siegel S., Coenen-Stass A., Pertel T., Luban J., Mothes W. TRIM protein-mediated regulation of inflammatory and innate immune signaling and its association with antiretroviral activity. J. Virol. 2013;87:257–272. doi: 10.1128/JVI.01804-12.
    1. Portilho D.M., Fernandez J., Ringeard M., Machado A.K., Boulay A., Mayer M., Müller-Trutwin M., Beignon A.-S., Kirchhoff F., Nisole S., et al. Endogenous TRIM5α function is regulated by SUMOylation and nuclear sequestration for efficient innate sensing in dendritic cells. Cell Rep. 2016;14:355–369. doi: 10.1016/j.celrep.2015.12.039.
    1. Jimenez-Moyano E., Ruiz A., Kløverpris H.N., Rodriguez-Plata M.T., Peña R., Blondeau C., Selwood D.L., Izquierdo-Useros N., Moris A., Clotet B., et al. Nonhuman TRIM5 variants enhance recognition of HIV-1-infected cells by CD8+ T cells. J. Virol. 2016;90:8552–8562. doi: 10.1128/JVI.00819-16.
    1. Norman J.M., Mashiba M., McNamara L.A., Onafuwa-Nuga A., Chiari-Fort E., Shen W., Collins K.L. The antiviral factor APOBEC3G enhances the recognition of HIV-infected primary T cells by natural killer cells. Nat. Immunol. 2011;12:975–983. doi: 10.1038/ni.2087.
    1. Casartelli N., Guivel-Benhassine F., Bouziat R., Brandler S., Schwartz O., Moris A. The antiviral factor APOBEC3G improves CTL recognition of cultured HIV-infected T cells. J. Exp. Med. 2010;207:39–49. doi: 10.1084/jem.20091933.
    1. Cardinaud S., Urrutia A., Rouers A., Coulon P.-G., Kervevan J., Richetta C., Bet A., Maze E.A., Larsen M., Iglesias M.-C., et al. Triggering of TLR-3, -4, NOD2, and DC-SIGN reduces viral replication and increases T-cell activation capacity of HIV-infected human dendritic cells. Eur. J. Immunol. 2017;47:818–829. doi: 10.1002/eji.201646603.
    1. Monajemi M., Woodworth C.F., Zipperlen K., Gallant M., Grant M.D., Larijani M. Positioning of APOBEC3G/F mutational hotspots in the human immunodeficiency virus genome favors reduced recognition by CD8+ T cells. PLoS ONE. 2014;9:e93428. doi: 10.1371/journal.pone.0093428.
    1. Grant M., Larijani M. Evasion of adaptive immunity by HIV through the action of host APOBEC3G/F enzymes. AIDS Res. Ther. 2017;14 doi: 10.1186/s12981-017-0173-8.
    1. Tokarev A., Suarez M., Kwan W., Fitzpatrick K., Singh R., Guatelli J. Stimulation of NF-κB activity by the HIV restriction factor BST2. J. Virol. 2013;87:2046–2057. doi: 10.1128/JVI.02272-12.
    1. Galão R.P., Le Tortorec A., Pickering S., Kueck T., Neil S.J.D. Innate sensing of HIV-1 assembly by Tetherin induces NFκB-dependent proinflammatory responses. Cell Host Microbe. 2012;12:633–644. doi: 10.1016/j.chom.2012.10.007.
    1. Sauter D., Hotter D., Van Driessche B., Stürzel C.M., Kluge S.F., Wildum S., Yu H., Baumann B., Wirth T., Plantier J.-C., et al. Differential regulation of NF-κB-mediated proviral and antiviral host gene expression by primate lentiviral Nef and Vpu proteins. Cell Rep. 2015;10:586–599. doi: 10.1016/j.celrep.2014.12.047.
    1. Li S.X., Barrett B.S., Heilman K.J., Messer R.J., Liberatore R.A., Bieniasz P.D., Kassiotis G., Hasenkrug K.J., Santiago M.L. Tetherin promotes the innate and adaptive cell-mediated immune response against retrovirus infection in vivo. J. Immunol. 2014;193:306–316. doi: 10.4049/jimmunol.1400490.
    1. Li S.X., Barrett B.S., Guo K., Kassiotis G., Hasenkrug K.J., Dittmer U., Gibbert K., Santiago M.L. Tetherin/BST-2 promotes dendritic cell activation and function during acute retrovirus infection. Sci. Rep. 2016;6:20425. doi: 10.1038/srep20425.
    1. Arias J.F., Heyer L.N., von Bredow B., Weisgrau K.L., Moldt B., Burton D.R., Rakasz E.G., Evans D.T. Tetherin antagonism by Vpu protects HIV-infected cells from antibody-dependent cell-mediated cytotoxicity. Proc. Natl. Acad. Sci. USA. 2014;111:6425–6430. doi: 10.1073/pnas.1321507111.
    1. Richard J., Prévost J., von Bredow B., Ding S., Brassard N., Medjahed H., Coutu M., Melillo B., Bibollet-Ruche F., Hahn B.H., et al. BST-2 expression modulates small CD4-mimetic sensitization of HIV-1-infected cells to antibody-dependent cellular cytotoxicity. J. Virol. 2017;91 doi: 10.1128/JVI.00219-17.
    1. Prévost J., Pickering S., Mumby M.J., Medjahed H., Gendron-Lepage G., Delgado G.G., Dirk B.S., Dikeakos J.D., Stürzel C.M., Sauter D., et al. Upregulation of BST-2 by type I interferons reduces the capacity of vpu to protect HIV-1-infected cells from NK cell responses. mBio. 2019;10 doi: 10.1128/mBio.01113-19.
    1. Lee H., Komano J., Saitoh Y., Yamaoka S., Kozaki T., Misawa T., Takahama M., Satoh T., Takeuchi O., Yamamoto N., et al. Zinc-finger antiviral protein mediates retinoic acid inducible gene I-like receptor-independent antiviral response to murine leukemia virus. Proc. Natl. Acad. Sci. USA. 2013;110:12379–12384. doi: 10.1073/pnas.1310604110.
    1. Shenoy A.R., Wellington D.A., Kumar P., Kassa H., Booth C.J., Cresswell P., MacMicking J.D. GBP5 promotes NLRP3 inflammasome assembly and immunity in mammals. Science. 2012;336:481–485. doi: 10.1126/science.1217141.
    1. Meunier E., Wallet P., Dreier R.F., Costanzo S., Anton L., Rühl S., Dussurgey S., Dick M.S., Kistner A., Rigard M., et al. Guanylate-binding proteins promote activation of the AIM2 inflammasome during infection with Francisella novicida. Nat. Immunol. 2015;16:476–484. doi: 10.1038/ni.3119.
    1. Feng J., Cao Z., Wang L., Wan Y., Peng N., Wang Q., Chen X., Zhou Y., Zhu Y. Inducible GBP5 mediates the antiviral response via interferon-related pathways during influenza a virus infection. J. Innate. Immun. 2017;9:419–435. doi: 10.1159/000460294.
    1. Rice G.I., Bond J., Asipu A., Brunette R.L., Manfield I.W., Carr I.M., Fuller J.C., Jackson R.M., Lamb T., Briggs T.A., et al. Mutations involved in Aicardi-Goutières syndrome implicate SAMHD1 as regulator of the innate immune response. Nat. Genet. 2009;41:829–832. doi: 10.1038/ng.373.
    1. Antonucci J.M., St Gelais C., Wu L. The dynamic interplay between HIV-1, SAMHD1, and the innate antiviral response. Front. Immunol. 2017;8:1541. doi: 10.3389/fimmu.2017.01541.
    1. Puigdomènech I., Casartelli N., Porrot F., Schwartz O. SAMHD1 restricts HIV-1 cell-to-cell transmission and limits immune detection in monocyte-derived dendritic cells. J. Virol. 2013;87:2846–2856. doi: 10.1128/JVI.02514-12.
    1. Chen S., Bonifati S., Qin Z., St Gelais C., Kodigepalli K.M., Barrett B.S., Kim S.H., Antonucci J.M., Ladner K.J., Buzovetsky O., et al. SAMHD1 suppresses innate immune responses to viral infections and inflammatory stimuli by inhibiting the NF-κB and interferon pathways. Proc. Natl. Acad. Sci. USA. 2018;115:E3798–E3807. doi: 10.1073/pnas.1801213115.
    1. Ayinde D., Bruel T., Cardinaud S., Porrot F., Prado J.G., Moris A., Schwartz O. SAMHD1 limits HIV-1 antigen presentation by monocyte-derived dendritic cells. J. Virol. 2015;89:6994–7006. doi: 10.1128/JVI.00069-15.
    1. Cao W., Bover L., Cho M., Wen X., Hanabuchi S., Bao M., Rosen D.B., Wang Y.-H., Shaw J.L., Du Q., et al. Regulation of TLR7/9 responses in plasmacytoid dendritic cells by BST2 and ILT7 receptor interaction. J. Exp. Med. 2009;206:1603–1614. doi: 10.1084/jem.20090547.
    1. Bego M.G., Côté É., Aschman N., Mercier J., Weissenhorn W., Cohen É.A. Vpu exploits the cross-talk between BST2 and the ILT7 receptor to suppress anti-HIV-1 responses by plasmacytoid dendritic cells. PLoS Pathog. 2015;11:e1005024. doi: 10.1371/journal.ppat.1005024.
    1. Jin S., Tian S., Luo M., Xie W., Liu T., Duan T., Wu Y., Cui J. Tetherin suppresses type I interferon signaling by targeting MAVS for NDP52-mediated selective autophagic degradation in human cells. Mol. Cell. 2017;68:308–322.e4. doi: 10.1016/j.molcel.2017.09.005.
    1. Wu T., Ma F., Ma X., Jia W., Pan E., Cheng G., Chen L., Sun C. Regulating innate and adaptive immunity for controlling SIV infection by 25-hydroxycholesterol. Front. Immunol. 2018;9:2686. doi: 10.3389/fimmu.2018.02686.

Source: PubMed

Спонсоры и соавторы

Заболевания

Медикаментозные вмешательства

Подписаться